Results 261 to 270 of about 125,716 (297)

The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging‐Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicenter Cohort Study in Japan

Hepatology Research, EarlyView.
In a multicenter cohort of 1059 patients, attenuation imaging (ATI) showed good diagnostic performance and strong correlation with MRI‐PDFF, supporting its value as a noninvasive method for evaluating hepatic steatosis. ABSTRACT Background Attenuation imaging (ATI) is used for the noninvasive diagnosis of hepatic steatosis (HS) based on the ultrasound ...
Takashi Nishimura, Hiroko Iijima, Yasuaki Suzuki, Kent Imajo, Tamami Abe, Hidekatsu Kuroda, Masashi Hirooka, Asako Nogami, Sadanobu Ogawa, Satoshi Oeda, Katsutoshi Sugimoto, Toshifumi Tada, Reiichiro Kondo, Tomoyuki Akita, Shigehiro Kokubu, Yoichi Hiasa, Atsushi Nakajima, Hidenori Toyoda, Hirokazu Takahashi, Yuichiro Eguchi, Hirohisa Yano, Junko Tanaka, Fuminori Moriyasu, Masayoshi Kage, Takashi Kumada   +24 more
wiley   +1 more source

Analysis of risk factors and correlation between the degree of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis. [PDF]

BMC Gastroenterol
Yang X, Xie D, Du Y, Zhang D, Chen H, Yuan Y.   +5 more
europepmc   +1 more source

Machine Learning Approach Enables Highly Accurate Identification of At‐Risk Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
ABSTRACT Aim At‐risk metabolic dysfunction‐associated steatohepatitis (MASH), characterized by significant activity and fibrosis, increases the risk of liver complications. Liver stiffness measurement (LSM), commonly used to detect significant fibrosis, has limitations in terms of accessibility and performance in certain populations.
Masaya Sato, Takuma Nakatsuka, Tatsuya Minami, Yotaro Kudo, Rie Irie, Hanako Tsujikawa, Takumi Kawaguchi, Hirokazu Takahashi, Yuichiro Eguchi, Eisuke Murakami, Kazuaki Chayama, Takeshi Okanoue, Michiie Sakamoto, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +15 more
wiley   +1 more source

Soluble Triggering Receptor Expressed on Myeloid Cells 2 is a Biomarker but Not a Mediator of Fibrosing Steatohepatitis. [PDF]

Gastro Hep Adv
Dempsey JL, Savard C, Kothari V, Tang J, Lee SP, Bornfeldt KE, Carr RM, Ioannou GN.   +7 more
europepmc   +1 more source

Guidance for Liver Rehabilitation in Chronic Liver Disease

Hepatology Research, EarlyView.
ABSTRACT In April 2023, the Japan Society of Hepatology published its official guidelines on liver rehabilitation for chronic liver disease. In this article, we summarize the current evidence on the role of liver rehabilitation in slowing the progression of chronic liver disease, particularly metabolic dysfunction‐associated steatotic liver disease ...
Shuji Terai, Hiroteru Kamimura, Yoichi Hiasa, Norio Akuta, Toru Ishikawa, Yuichiro Eguchi, Hironao Okubo, Takumi Kawaguchi, Miwa Kawanaka, Tatsuo Kanda, Masaaki Korenaga, Ryotaro Sakamori, Masahito Shimizu, Yoshio Sumida, Ryosuke Tateishi, Atsushi Tanaka, Naoki Tanaka, Yasuo Tanaka, Yuki Tahata, Masato Nakai, Tadashi Namisaki, Takashi Nishimura, Atsushi Hiraoka, Takeshi Matsui, Nami Mori, Akio Moriya, Tetsuo Takehara   +26 more
wiley   +1 more source

Prevalence and characteristics of metabolic dysfunction-associated steatohepatitis among pediatric patients in the MarketScan Databases. [PDF]

PLoS One
Peter-Marske KM, Zhang X, Wang T, Liu X, Fernandes G, Engel SS, Shankar R.   +6 more
europepmc   +1 more source

Modern Diets, Metabolic Inequity, and Race–Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is quickly emerging as a global public health concern, primarily fueled by the rising consumption of processed and ultraprocessed foods. This global health issue, showing a 50% increase in prevalence over two decades to 38% of the global population, is now the second most common ...
Arunkumar Krishnan, Kunal C. Kadakia, Sean Richard Rudnick, Andrew S. deLemos, James Dewitt Miller, Ted Xiao, Mark W. Russo, Dionisios Vrochides, Andrew Schreiner, Ajay Dharod   +9 more
wiley   +1 more source

Metabolic surgery in metabolic dysfunction-associated steatohepatitis: emerging evidence and clinical promise. [PDF]

Hepatobiliary Surg Nutr
Fukushima M, Miuma S, Miyaaki H.
europepmc   +1 more source

Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases

Journal of Gastroenterology and Hepatology, EarlyView.
Liver diseases are a major global health challenge, with current treatments inadequate. This review highlights the role of bacterial extracellular vesicles in liver inflammation, fibrosis, and metabolism. We also explore these from commensals and probiotics, their protective effects, and discuss research challenges and future therapeutic potential ...
Yakun Li, Jia Li, Robin P. F. Dullaart, Han Moshage   +3 more
wiley   +1 more source

Cuproptosis as a Potential Therapeutic Target for Steatotic Liver Disease. [PDF]

Biomolecules
Pan Y, Luo C, Guo Q, Duan Q, Wu Z, Li Y.
europepmc   +1 more source